PrimaryMarkets welcomes you to the Imugene Investor Centre. We are actively supporting awareness and promotion of this ASX-listed biopharmaceutical company.

The Imugene Board of Directors have directed PrimaryMarkets to introduce Imugene to all those interested.

Imugene (ASX:IMU) is an immuno-oncology focused biopharmaceutical company developing various cancer immunotherapies. Their mission is to build a pipeline of B-cell peptide cancer vaccines and therapeutics with lead products such as – HER-Vaxx – a proprietary therapeutic cancer immunotherapy that stimulates a polyclonal antibody response. Imugene is also developing a B cell vaccine, KEY-Vaxx.
To view the Imugene share price, announcements, presentation/reports, commentary note, news and videos, please use the Imugene navigation bar on the side panel. 






Animoca Brands


Become a Follower